An official website of the United States government
Home
Name
mini-BEAM
Alternate names
BEAM
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for mini-BEAM
Name
Alternate Names
Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar
Abbreviations
EPEG
VP-16
VP-16-213
Category
Chemotherapy
Subcategory
Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid
NSC Number
141540
Primary Site
Gastric cancer
Hodgkins lymphoma
Lung cancer (NSCLC, SCLC)
Non-Hodgkin lymphoma
testicular cancer (Germ cell tumors)
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Alanine mustard
Alkeran
CB-3025
DL Sarcolysine
DL-O-Sarcolysin
L-Phenylalanine Mustard
L-Sarcolysin
Melfalan
Phenylalanine Mustard
Sarcolysine
Sarkoklorin
Sarkolizin
WR-19813
Abbreviations
L-PAM
MPL
PAM
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
8806
008806
57199
Primary Site
Histology
None
Remarks
Alkylating antineoplastic agent. FDA approved uses on multiple myeloma and epithelial non-resectable ovarian carcinoma.
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard
Coding
This drug should be coded
Name
Alternate Names
AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453
Abbreviations
ara-C
CA
HDA
HDARA-C
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
063878
63878
Primary Site
Histology
None
Remarks
Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)
Coding
This drug should be coded
Name
Alternate Names
BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021
Abbreviations
BCNU
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
409962
Primary Site
Histology
None
Remarks
Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)
Coding
This drug should be coded
